


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INCLUSION IN CHINA SECURITIES INDEX SERIES

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that InSilico Medicine has been included in China Securities Index (CSI) Series, including CSI Hong Kong Connect Innovative Drug Index (Code: 931250), CSI Hong Kong Brand Name Drug Index (Code: 931787), and CSI HK Connect Health Care Composite Index (Code: 930965) (the “**Inclusion**”). The Inclusion has been effective on June 15, 2026 (Monday).

Since the listing on The Stock Exchange of Hong Kong Limited, InSilico Medicine has been included into several major index series before being recognized by the CSI Series, namely, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng Biotechnology Index, FTSE Global Small Cap Index, FTSE Global All Cap Index, and FTSE Global Total Cap Index.

The Board believes that the Company’s inclusion across the index series reflects market recognition of its steady fundamentals, technological capabilities, and development potential. These inclusions are expected to broaden the Company’s exposure among international institutional investors and research analysts, attract capital inflows from passive funds tracking the indexes, diversify the shareholder base, and improve trading liquidity for its shares.

The Board appreciates the continued support from the shareholders and investors of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, June 15, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.